Blockchain Registration Transaction Record

GeoVax Accelerates Mpox Vaccine Development Amid Global Crisis

GeoVax Labs accelerates GEO-MVA Mpox vaccine development amid global surge and WHO emergency status, aiming for scalable, equitable solutions.

The global surge in Mpox cases, especially in Africa, and the emergence of more virulent strains highlight the urgent need for effective and scalable vaccine solutions. GeoVax's accelerated development of the GEO-MVA vaccine, supported by the European Medicines Agency, represents a critical step towards addressing the vaccine shortage and ensuring equitable access. This development is vital for preventing further spread of the disease, reducing strain on overwhelmed healthcare systems, and protecting vulnerable populations worldwide.